¼¼°èÀÇ ½Å°æ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå
Neurological Biomarkers
»óǰÄÚµå : 1775033
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 389 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,239,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,719,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°è ½Å°æ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀº 2030³â±îÁö 171¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 88¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ½Å°æ ¹ÙÀÌ¿À¸¶Ä¿ ¼¼°è ½ÃÀåÀº 2024-2030³âÀÇ ºÐ¼® ±â°£¿¡ CAGR 11.7%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 171¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ À¯Àüü ¹ÙÀÌ¿À¸¶Ä¿´Â CAGR 9.9%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á±îÁö 75¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ´Ü¹éÁúüÇÐ ¹ÙÀÌ¿À¸¶Ä¿ ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 14.5%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 24¾ï ´Þ·¯, Áß±¹Àº CAGR 15.5%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹Ãø

¹Ì±¹ÀÇ ½Å°æ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀº 2024³â¿¡´Â 24¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR 15.5%·Î ¼ºÀåÀ» Áö¼ÓÇÏ¿©, 2030³â±îÁö 35¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 8.7%¿Í 10.3%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 9.2%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

¼¼°è ½Å°æ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ Á¤¸®

½Å°æ ¹ÙÀÌ¿À¸¶Ä¿°¡ ³úÁúȯÀÇ Áø´Ü°ú Ä¡·á¸¦ À籸¼ºÇÏ´Â ÀÌÀ¯´Â ¹«¾ùÀϱî?

½Å°æ ¹ÙÀÌ¿À¸¶Ä¿´Â ¾ËÃ÷ÇÏÀ̸Ӻ´, ÆÄŲ½¼º´, ¿Ü»ó¼º ³ú¼Õ»ó, ´Ù¹ß¼º °æÈ­Áõ¿¡ À̸£±â±îÁö ´Ù¾çÇÑ ½Å°æÁúȯÀÇ Áø´Ü, ¸ð´ÏÅ͸µ, Ä¡·á¿¡ ÇʼöÀûÀÎ µµ±¸·Î µîÀåÇß½À´Ï´Ù. À¯ÀüÇÐÀû, ´Ü¹éÁúÇÐÀû, ´ë»çÇÐÀû, ¿µ»ó ±â¹Ý ÁöÇ¥¸¦ Æ÷ÇÔÇÑ ÀÌ·¯ÇÑ ¹ÙÀÌ¿À¸¶Ä¿´Â ³ú ÁúȯÀÇ º´Å»ý¸®¿¡ ´ëÇÑ ±ÍÁßÇÑ ÅëÂû·ÂÀ» Á¦°øÇÏ¿© º¸´Ù ºü¸£°í Á¤È®ÇÑ Áø´ÜÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ÁÖ°üÀûÀÎ ÀÓ»ó °üÂû¿¡ ÀÇÁ¸ÇÏ´Â ±âÁ¸ÀÇ Áø´Ü ¹æ½Ä°ú ´Þ¸®, ½Å°æ ¹ÙÀÌ¿À¸¶Ä¿´Â Á¤¹ÐÀÇ·á ÀÌ´Ï¼ÅÆ¼ºê¸¦ °­È­ÇÒ ¼ö ÀÖ´Â °´°üÀûÀ̰í Á¤·®ÀûÀÎ µ¥ÀÌÅ͸¦ Á¦°øÇÕ´Ï´Ù. ³úô¼ö¾×(CSF) ¹× Ç÷¾× ±â¹Ý ¹ÙÀÌ¿À¸¶Ä¿ÀÇ »ç¿ëÀº ȯÀÚÀÇ ¼øÀÀµµ¸¦ Çâ»ó½ÃŰ´Â ºñħ½ÀÀû, Àúħ½ÀÀû Áø´Ü ¹æ¹ýÀ» °¡´ÉÇÏ°Ô ÇÏ¿© Àα⸦ ²ø°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¾çÀüÀÚ¹æ»ç¼±´ÜÃþÃÔ¿µ(PET) ¹× ±â´ÉÀû MRI(fMRI)¿Í °°Àº ½Å°æ ¿µ»ó Áø´ÜÀÇ ¹ßÀüÀ¸·Î ¹ÙÀÌ¿À¸¶Ä¿ ¿¬±¸°¡ È®´ëµÇ¾î ÀÓ»óÀǰ¡ ½Ç½Ã°£À¸·Î Áúº´ÀÇ ÁøÇàÀ» ÃßÀûÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¹ÙÀÌ¿À¸¶Ä¿ ºÐ¼®¿¡ ÀΰøÁö´É(AI)À» ÅëÇÕÇÏ´Â ¹ßÀüÀº ÀÌ ºÐ¾ß¿¡ ¶Ç ´Ù¸¥ º¯È­¸¦ °¡Á®¿ÔÀ¸¸ç, ±âÁ¸ ¹æ¹ýÀ¸·Î´Â ¾Ë¾ÆÂ÷¸± ¼ö ¾ø¾ú´ø Áúº´°ú °ü·ÃµÈ ¹Ì¹¦ÇÑ º¯È­¸¦ °¨ÁöÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. Á¶±â ¹ß°ß ¹× ¸ÂÃã Ä¡·á Àü·«¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ½Å°æ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀº Çö´ë ½Å°æÇÐÀÇ ÇÙ½ÉÀÌ µÇ¾î ȯÀÚ ¿¹ÈÄ¿Í Ä¡·á È¿°ú¸¦ Å©°Ô Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù.

½Å°æ ¹ÙÀÌ¿À¸¶Ä¿ÀÇ º¸±ÞÀ» °¡·Î¸·´Â °úÁ¦´Â ¹«¾ùÀϱî?

ÀÌ·¯ÇÑ ÀáÀç·Â¿¡µµ ºÒ±¸Çϰí, ½Å°æ ¹ÙÀÌ¿À¸¶Ä¿´Â ÀÓ»óÀû äÅðú º¸±Þ¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¸î °¡Áö °úÁ¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ÁÖ¿ä Àå¾Ö¹° Áß Çϳª´Â ½Å°æÁúȯÀÇ º¹À⼺ÀÔ´Ï´Ù. ¸¹Àº Áúº´Àº Áõ»óÀÌ Áߺ¹µÇ°í ¿øÀεµ ´ÙÀÎÀÚÀ̱⠶§¹®¿¡ ƯÀ̼ºÀÌ ³ô°í ½Å·ÚÇÒ ¼ö ÀÖ´Â ¹ÙÀÌ¿À¸¶Ä¿¸¦ °³¹ßÇÏ±â ¾î·Æ½À´Ï´Ù. ¶ÇÇÑ, ¹ÙÀÌ¿À¸¶Ä¿ÀÇ °ËÁõ ¹× Ç¥ÁØÈ­¿¡ ÇÊ¿äÇÑ ³ôÀº ºñ¿ë°ú ±â¼ú Àü¹® Áö½ÄÀº ƯÈ÷ ÀÚ¿øÀÌ ºÎÁ·ÇÑ ÀÇ·á ȯ°æ¿¡¼­ Å« À庮ÀÌ µÇ°í ÀÖ½À´Ï´Ù. ´Ù¾çÇÑ È¯ÀÚ Áý´Ü°ú ½ÇÇè½Ç ȯ°æ¿¡¼­ÀÇ ¹ÙÀÌ¿À¸¶Ä¿ ÃøÁ¤ÀÇ ÆíÂ÷´Â ÀÓ»ó Àû¿ëÀ» ´õ¿í º¹ÀâÇÏ°Ô ¸¸µé°í, ÀçÇö¼º ¹× ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀο¡ ´ëÇÑ ¿ì·Á¸¦ ¾ß±âÇÕ´Ï´Ù. ¶Ç ´Ù¸¥ °úÁ¦´Â »õ·Î¿î ¹ÙÀÌ¿À¸¶Ä¿ÀÇ ¿¹Ãø ¹× Áø´ÜÀû °¡Ä¡¸¦ È®¸³Çϱâ À§Çؼ­´Â º¸´Ù ´ë±Ô¸ðÀÇ Àß ÅëÁ¦µÈ ÀÓ»ó ¿¬±¸°¡ ÇÊ¿äÇÏ´Ù´Â Á¡ÀÔ´Ï´Ù. ¹ÙÀÌ¿À¸¶Ä¿ ±â¹Ý Áø´Ü °Ë»ç¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ ´À¸° ½ÂÀÎ ¼Óµµµµ ½ÃÀå ÁøÀÔÀ» Áö¿¬½Ã۰í ÃÖ÷´Ü Áø´Ü µµ±¸ÀÇ »ç¿ëÀ» Á¦ÇÑÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¸¹Àº ±¹°¡¿¡¼­ ¹ÙÀÌ¿À¸¶Ä¿ °Ë»ç¿¡ ´ëÇÑ º¸ÇèÀÌ Àû¿ëµÇÁö ¾Ê´Â °æ¿ì°¡ ¸¹±â ¶§¹®¿¡ ȯÀÚ Á¢±Ù¼ºÀÌ ¿©ÀüÈ÷ ¹®Á¦Á¡À¸·Î ÁöÀûµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹®Á¦¸¦ ÇØ°áÇϱâ À§Çؼ­´Â ¿¬±¸ÀÚ, ±ÔÁ¦ ±â°ü, ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü°¡ Çù·ÂÇÏ¿© Ç¥ÁØÈ­µÇ°í, ºñ¿ë È¿À²ÀûÀ̸ç, ÀÓ»óÀû Ÿ´ç¼ºÀÌ ÀÔÁõµÈ ½Å°æÇÐÀû ¹ÙÀÌ¿À¸¶Ä¿ ¼Ö·ç¼ÇÀ» °³¹ßÇØ¾ß ÇÕ´Ï´Ù.

±â¼ú Çõ½ÅÀº ½Å°æÇÐ ¹ÙÀÌ¿À¸¶Ä¿ ¿¬±¸¸¦ ¾î¶»°Ô º¯È­½Ã۰í Àִ°¡?

À¯Àüü, ´Ü¹éÁúüÇÐ, ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½ºÀÇ Çõ½ÅÀº »õ·Î¿î ¹ÙÀÌ¿À¸¶Ä¿ÀÇ ¹ß°ß°ú Àû¿ëÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. °¡Àå À¯¸ÁÇÑ ¹ßÀü Áß Çϳª´Â Ç÷¾×, Ÿ¾×, ¼Òº¯¿¡¼­ ½Å°æ ¹ÙÀÌ¿À¸¶Ä¿¸¦ °ËÃâÇÒ ¼ö ÀÖ´Â ¾×ü »ý°Ë ±â¼úÀÇ °³¹ß·Î, ±âÁ¸ÀÇ ¼ö¾× ±â¹Ý °Ë»ç¸¦ ´ëüÇÒ ¼ö ÀÖ´Â ºñħ½ÀÀû °Ë»ç¸¦ Á¦°øÇϰí ÀÖÀ¸¸ç, AI¿Í ¸Ó½Å·¯´× ¾Ë°í¸®Áòµµ ¹ÙÀÌ¿À¸¶Ä¿ÀÇ ¹ß°ß°ú ºÐ¼®¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ½Å°æÅðÇ༺ Áúȯ°ú °ü·ÃµÈ º¹ÀâÇÑ ¹ÙÀÌ¿À¸¶Ä¿ ÆÐÅÏÀÇ ½Äº°À» °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. À¯Àüü, Àü»çü, ÇÁ·ÎÅ׿È, ´ë»çü µ¥ÀÌÅ͸¦ °áÇÕÇÑ ¸ÖƼ¿À¹Í½º Á¢±Ù¹ýÀÇ ÅëÇÕÀº ¹ÙÀÌ¿À¸¶Ä¿ ¿¬±¸¸¦ ´õ¿í °­È­ÇÏ¿© Áúº´ ¸ÞÄ¿´ÏÁò¿¡ ´ëÇÑ º¸´Ù Á¾ÇÕÀûÀÎ ÀÌÇØ¸¦ °¡Á®¿À°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿þ¾î·¯ºí ½Å°æ ±â¼ú ¹× µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿´Â ½ÇÁ¦ ȯ°æ¿¡¼­ ½Å°æ ±â´ÉÀ» Áö¼ÓÀûÀ¸·Î ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖµµ·Ï ÇÏ´Â µ¥¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº Áúº´ÀÇ Á¶±â ¹ß°ß°ú ¸ð´ÏÅ͸µÀ» °³¼±ÇÒ »Ó¸¸ ¾Æ´Ï¶ó, °³Àκ° ¹ÙÀÌ¿À¸¶Ä¿ ÇÁ·ÎÆÄÀÏ¿¡ µû¶ó Ä¡·á¸¦ Á¶Á¤ÇÏ´Â Á¤¹ÐÀÇ·áÀÇ ±æÀ» ¿­¾îÁÖ°í ÀÖ½À´Ï´Ù. ¾÷°è°¡ ÷´Ü ±â¼úÀ» °è¼Ó µµÀÔÇÔ¿¡ µû¶ó ½Å°æÇÐÀÇ ¹Ì·¡¸¦ Çü¼ºÇÏ´Â ½Å°æ ¹ÙÀÌ¿À¸¶Ä¿ÀÇ ¿ªÇÒÀÌ Á¡Á¡ ´õ Áß¿äÇØÁö°í ÀÖ½À´Ï´Ù.

½Å°æ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀÇ ¼ºÀå ¿øµ¿·ÂÀº?

½Å°æ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀÇ ¼ºÀåÀº ½Å°æÅðÇ༺ ÁúȯÀÇ À¯º´·ü Áõ°¡, °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ¹ÙÀÌ¿À¸¶Ä¿ °ËÃâ ±â¼úÀÇ ¹ßÀü µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ¾ËÃ÷ÇÏÀ̸Ӻ´, ÆÄŲ½¼º´, ±âŸ ³ëÈ­ °ü·Ã ½Å°æÁúȯÀÇ Àü ¼¼°èÀû ±ÞÁõÀº Á¶±â Áø´Ü µµ±¸ÀÇ Çʿ伺À» ºÒ·¯ÀÏÀ¸Å°°í ¹ÙÀÌ¿À¸¶Ä¿ÀÇ ¿¬±¸ °³¹ßÀ» °¡¼ÓÈ­½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½Å°æÁúȯ¿¡ ÃÊÁ¡À» ¸ÂÃá ÀÓ»ó½ÃÇèÀÇ È®´ë¿Í Á¦¾à»çµéÀÌ Ä¡·á ¼º°ú Çâ»óÀ» À§ÇØ ¹ÙÀÌ¿À¸¶Ä¿ ±â¹Ý ÀǾàǰ °³¹ß Àü·«¿¡ ÅõÀÚÇϰí ÀÖ´Â °Íµµ ½ÃÀå °³Ã´¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, FDA ¹× EMA¿Í °°Àº ±â°üÀÌ ÀÓ»ó½ÃÇè ¹× Á¤¹ÐÀÇ·á ÇÁ·Î±×·¥¿¡ ¹ÙÀÌ¿À¸¶Ä¿ÀÇ ÅëÇÕÀ» Àå·ÁÇϸ鼭 ¹ÙÀÌ¿À¸¶Ä¿ ±â¹Ý Áø´Ü¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ Áö¿øµµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿¿Í ¿ø°Ý ¸ð´ÏÅ͸µ ¼Ö·ç¼ÇÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÀÎÁö ¹× ¿îµ¿ ±â´ÉÀÇ ½Ç½Ã°£ ÃßÀûÀÌ °¡´ÉÇØÁü¿¡ µû¶ó ½ÃÀå ±âȸ´Â ´õ¿í È®´ëµÇ°í ÀÖ½À´Ï´Ù. Á¤ºÎ ±â°ü°ú ¹Î°£ ´ÜüÀÇ ÀÚ±Ý Áö¿ø Áõ°¡´Â ¹ÙÀÌ¿À¸¶Ä¿ ¹ß±¼ ³ë·ÂÀ» Áö¿øÇϰí Çаè, »ý¸í°øÇÐ ±â¾÷, ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü °£ÀÇ Çù¾÷À» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ±â¼ú Çõ½ÅÀÌ ½Å°æ ¹ÙÀÌ¿À¸¶Ä¿ÀÇ Á¤È®¼º, Á¢±Ù¼º, ÀÓ»óÀû À¯¿ë¼ºÀ» Áö¼ÓÀûÀ¸·Î Çâ»ó½ÃŰ¸é¼­ ½ÃÀåÀº Å©°Ô ¼ºÀåÇϰí ÀÖÀ¸¸ç, ½Å°æÇÐ ¹× Á¤¹Ð Áø´Ü ºÐ¾ß¿¡¼­ ´ÙÀ½ ´Ü°èÀÇ Áøº¸¸¦ ÁÖµµÇÒ Áغñ°¡ µÇ¾î ÀÖ½À´Ï´Ù.

ºÎ¹®

¹ÙÀÌ¿À¸¶Ä¿ À¯Çü(À¯Àüü ¹ÙÀÌ¿À¸¶Ä¿, ´Ü¹éÁúüÇÐ ¹ÙÀÌ¿À¸¶Ä¿, ¸ÞŸº¸·Ò¹ÙÀÌ¿À¸¶Ä«, À̹Ì¡ ¹ÙÀÌ¿À¸¶Ä¿, ±âŸ ¹ÙÀÌ¿À¸¶Ä¿), ¿ëµµ(¾ËÃ÷ÇÏÀÌ¸Ó º´, ÆÄŲ½¼º´, ´Ù¹ß¼º °æÈ­Áõ, ÀÚÆóÁõ ½ºÆåÆ®·³, ±âŸ ¿ëµµ), ÃÖÁ¾ ¿ëµµ(º´¿ø¡¤º´¿ø ¿¬±¸¼Ò ÃÖÁ¾ ¿ëµµ, µ¶¸³°è ÀÓ»ó Áø´Ü¼¾ÅÍ ÃÖÁ¾ ¿ëµµ, ¿¬±¸±â°ü ÃÖÁ¾ ¿ëµµ, ±âŸ ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ¼­, ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ Å¥·¹ÀÌÆ®µÈ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Neurological Biomarkers Market to Reach US$17.1 Billion by 2030

The global market for Neurological Biomarkers estimated at US$8.8 Billion in the year 2024, is expected to reach US$17.1 Billion by 2030, growing at a CAGR of 11.7% over the analysis period 2024-2030. Genomic Biomarkers, one of the segments analyzed in the report, is expected to record a 9.9% CAGR and reach US$7.5 Billion by the end of the analysis period. Growth in the Proteomic Biomarkers segment is estimated at 14.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.4 Billion While China is Forecast to Grow at 15.5% CAGR

The Neurological Biomarkers market in the U.S. is estimated at US$2.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.5 Billion by the year 2030 trailing a CAGR of 15.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.7% and 10.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.2% CAGR.

Global Neurological Biomarkers Market - Key Trends & Drivers Summarized

Why Are Neurological Biomarkers Reshaping the Diagnosis and Treatment of Brain Disorders?

Neurological biomarkers have emerged as critical tools for diagnosing, monitoring, and treating various neurological disorders, ranging from Alzheimer’s disease and Parkinson’s disease to traumatic brain injuries and multiple sclerosis. These biomarkers, which include genetic, proteomic, metabolomic, and imaging-based indicators, provide valuable insights into the pathophysiology of brain diseases, allowing for earlier and more accurate diagnoses. Unlike traditional diagnostic approaches that often rely on subjective clinical observations, neurological biomarkers offer objective, quantifiable data that enhance precision medicine initiatives. The use of cerebrospinal fluid (CSF) and blood-based biomarkers is gaining traction, enabling non-invasive and minimally invasive diagnostic methods that improve patient compliance. Additionally, advancements in neuroimaging, such as positron emission tomography (PET) and functional MRI (fMRI), have expanded biomarker research, allowing clinicians to track disease progression in real-time. The growing integration of artificial intelligence (AI) in biomarker analysis is further revolutionizing the field, making it possible to detect subtle disease-related changes that might go unnoticed through conventional methods. As demand for early detection and personalized treatment strategies increases, the neurological biomarkers market is becoming a cornerstone of modern neurology, significantly improving patient outcomes and treatment efficacy.

What Challenges Are Hindering the Widespread Adoption of Neurological Biomarkers?

Despite their potential, neurological biomarkers face several challenges that impact their clinical adoption and widespread use. One of the major obstacles is the complexity of neurological disorders, as many conditions have overlapping symptoms and multifactorial causes, making it difficult to develop highly specific and reliable biomarkers. Additionally, the high cost and technical expertise required for biomarker validation and standardization pose significant barriers, particularly in resource-limited healthcare settings. Variability in biomarker measurements across different patient populations and laboratory settings further complicates their clinical implementation, leading to concerns about reproducibility and regulatory approval. Another challenge is the need for larger, well-controlled clinical studies to establish the predictive and diagnostic value of emerging biomarkers. The slow pace of regulatory approvals for biomarker-based diagnostic tests also delays market entry, restricting the availability of cutting-edge diagnostic tools. Furthermore, patient accessibility remains an issue, as biomarker testing is not yet widely covered by insurance providers in many countries. Addressing these challenges requires greater collaboration between researchers, regulatory bodies, and healthcare providers to develop standardized, cost-effective, and clinically validated neurological biomarker solutions.

How Are Technological Innovations Transforming Neurological Biomarker Research?

The field of neurological biomarkers is undergoing a technological revolution, with innovations in genomics, proteomics, and bioinformatics accelerating the discovery and application of novel biomarkers. One of the most promising advancements is the development of liquid biopsy techniques, which allow for the detection of neurological biomarkers in blood, saliva, or urine, providing a non-invasive alternative to traditional CSF-based testing. AI and machine learning algorithms are also playing a critical role in biomarker discovery and analysis, enabling the identification of complex biomarker patterns associated with neurodegenerative diseases. The integration of multi-omics approaches, which combine genomic, transcriptomic, proteomic, and metabolomic data, is further enhancing biomarker research, providing a more comprehensive understanding of disease mechanisms. Additionally, wearable neurotechnology and digital biomarkers are gaining momentum, allowing continuous monitoring of neurological function in real-world settings. These advancements are not only improving early detection and disease monitoring but also paving the way for precision medicine approaches that tailor treatments based on an individual’s unique biomarker profile. As the industry continues to embrace cutting-edge technologies, the role of neurological biomarkers in shaping the future of neurology is becoming increasingly significant.

What Is Driving the Growth of the Neurological Biomarkers Market?

The growth in the neurological biomarkers market is driven by several factors, including the rising prevalence of neurodegenerative diseases, increasing demand for personalized medicine, and advancements in biomarker detection technologies. The global surge in Alzheimer’s disease, Parkinson’s disease, and other age-related neurological disorders is fueling the need for early diagnostic tools, accelerating biomarker research and development. The expansion of clinical trials focused on neurological diseases is also contributing to market growth, as pharmaceutical companies invest in biomarker-based drug development strategies to improve therapeutic outcomes. Additionally, regulatory support for biomarker-driven diagnostics is increasing, with agencies such as the FDA and EMA encouraging the integration of biomarkers into clinical trials and precision medicine programs. The growing adoption of digital biomarkers and remote monitoring solutions is further expanding market opportunities, enabling real-time tracking of cognitive and motor functions. Increased funding from government and private organizations is also supporting biomarker discovery efforts, fostering collaborations between academia, biotech firms, and healthcare providers. As technological innovations continue to enhance the accuracy, accessibility, and clinical utility of neurological biomarkers, the market is poised for significant expansion, driving the next wave of advancements in neurology and precision diagnostics.

SCOPE OF STUDY:

The report analyzes the Neurological Biomarkers market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Biomarkers Type (Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers, Other Biomarkers); Application (Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Autism Spectrum Disorder, Other Applications); End-Use (Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â